KRAS MUTATION-RELATED TUMORS
Clinical trials for KRAS MUTATION-RELATED TUMORS explained in plain language.
Never miss a new study
Get alerted when new KRAS MUTATION-RELATED TUMORS trials appear
Sign up with your email to follow new studies for KRAS MUTATION-RELATED TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat cancers: drug combo targets KRAS mutation
Disease control Recruiting nowThis early-phase study tests the safety and best dose of a new drug combination (NEROFE and doxorubicin) in adults with advanced solid tumors that have a KRAS mutation and ST2 protein. About 24 participants whose cancer has worsened after standard treatments will receive weekly d…
Matched conditions: KRAS MUTATION-RELATED TUMORS
Phase: PHASE1 • Sponsor: Georgetown University • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
New pill targets hard-to-treat cancers with KRAS and BRAF mutations
Disease control Recruiting nowThis early-phase study tests an oral drug called S241656 in adults with advanced cancers that have certain gene changes (KRAS, BRAF, and others). The drug is given alone or with other cancer treatments. The goal is to find safe doses and see if the drug shrinks tumors. About 554 …
Matched conditions: KRAS MUTATION-RELATED TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated May 12, 2026 13:40 UTC